SL Science Holding Ltd
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- SL Science Holding Limited, a Cayman Islands exempted holding company, operates as the post-business combination entity formed to own and control SL BIO Ltd., a biomedical company focused on cell and gene therapy platforms. The company engages in the development and commercialization of off-the-shelf gamma-delta T cell therapies and other cellular therapies targeting solid tumor indications, including pancreatic and brain cancers, with strategic capital and governance support from merged entities. Core activities include acquiring, owning, and coordinating SL BIO Ltd.’s clinical and commercial pipeline, providing overarching management, and pursuing partnerships, licensing, and financing to advance clinical development, regulatory filing, and eventual market commercialization. The group’s geographic footprint spans global operations through its subsidiaries and partnerships, with a headquarters presence in key financial centers enabling access to international capital markets. SL Science Holding Limited is publicly positioned to list on major exchanges, leveraging investor relations and strategic partnerships to support its growth trajectory in oncology therapeutics and biotech innovations. Founding year and headquarters are associated with its formation through a SPAC merger process, positioning the company to scale SL BIO Ltd.’s pipeline and accelerate clinical development, manufacturing scale-up, and potential commercial deployment. Subsidiaries and parent relationships include SL BIO Ltd. as the core operating entity, with governance and strategic oversight provided by the post-merger holding company.
Company News
SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company
SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform
SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in Glioblastoma
SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology
SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma
SL Science Holding, Alamos Gold And Other Big Stocks Moving Lower In Monday's Pre-Market Session
SL Science Holding Limited Reports Full Year 2025 Financial Results
SL BIO Ltd. and Horizon Space Acquisition II Announce Closing of Business Combination and Listing on the Nasdaq Global Market